RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA)...

Full description

Bibliographic Details
Main Authors:	Simona Lamba, Mariangela Russo, Chong Sun, Luca Lazzari, Carlotta Cancelliere, Wipawadee Grernrum, Cor Lieftink, Rene Bernards, Federica Di Nicolantonio, Alberto Bardelli
Format:	Article
Language:	English
Published:	Elsevier 2014-09-01
Series:	Cell Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124714006172

Similar Items

A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
by: Tonći Šuštić, et al.
Published: (2018-11-01)

Correction to: A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers
by: Tonći Šuštić, et al.
Published: (2021-02-01)

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
by: Irem Ozkan-Dagliyan, et al.
Published: (2020-06-01)

Targeting KRAS‐mutant pancreatic cancer through simultaneous inhibition of KRAS, MEK, and JAK2
by: Satoru Miyazaki, et al.
Published: (2025-02-01)

RAF dimer inhibition enhances the antitumor activity of MEK inhibitors in K‐RAS mutant tumors
by: Xi Yuan, et al.
Published: (2020-08-01)

SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers
by: Greg G. Jones, et al.
Published: (2019-06-01)

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
by: Eszter Molnár, et al.
Published: (2018-05-01)

Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
by: Juanjuan Feng, et al.
Published: (2023-03-01)

Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature
by: Reinhard Büttner, et al.
Published: (2023-12-01)

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
by: Hiroshi Kotani, et al.
Published: (2024-07-01)

Macrophage migration inhibitory factor promotes resistance to MEK blockade in KRAS mutant colorectal cancer cells
by: Seul‐Ki Cheon, et al.
Published: (2018-08-01)

PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation
by: Xiaojuan Wang, et al.
Published: (2020-08-01)

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
by: Ufuk Degirmenci, et al.
Published: (2020-01-01)

Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers
by: Hiroshi Kotani, et al.
Published: (2024-09-01)

Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers
by: Katarzyna M. Tyc, et al.
Published: (2023-03-01)

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
by: Hyejin Choi, et al.
Published: (2019-04-01)

The quaternary assembly of KRas4B with Raf-1 at the membrane
by: Hyunbum Jang, et al.
Published: (2020-01-01)

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
by: S. Lindsey eDavis, et al.
Published: (2015-06-01)

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth
by: Rameswari Chilamakuri, et al.
Published: (2022-09-01)

BRAF Splice Variant Resistance to RAF Inhibitor Requires Enhanced MEK Association
by: Michael J. Vido, et al.
Published: (2018-11-01)

Activity-Based Proteomics Reveals Heterogeneous Kinome and ATP-Binding Proteome Responses to MEK Inhibition in KRAS Mutant Lung Cancer
by: Jae-Young Kim, et al.
Published: (2016-04-01)

ADAM17-Dependent c-MET-STAT3 Signaling Mediates Resistance to MEK Inhibitors in KRAS Mutant Colorectal Cancer
by: Sandra Van Schaeybroeck, et al.
Published: (2014-06-01)

KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
by: Timothy H. Tran, et al.
Published: (2021-02-01)

Treatment of RAF1-Related Obstructive Hypertrophic Cardiomyopathy by MEK Inhibition Using Trametinib
by: Omid Kiamanesh, MD, et al.
Published: (2024-07-01)

Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet.
by: Grant A. McArthur
Published: (2015-07-01)

Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation
by: Thomas Yul Avery, et al.
Published: (2022-07-01)

Detection of activating mutations in RAS/RAF/MEK/ERK and JAK/STAT signaling pathways
by: K. I. Zarubina, et al.
Published: (2020-09-01)

Deregulation of a Network of mRNA and miRNA Genes Reveals That CK2 and MEK Inhibitors May Synergize to Induce Apoptosis KRAS-Active NSCLC
by: Madeline Krentz Gober, et al.
Published: (2019-05-01)

PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
by: Anirudh Prahallad, et al.
Published: (2015-09-01)

EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells.
by: Yvonne Möller, et al.
Published: (2014-01-01)

Bilateral blockade of MEK- and PI3K-mediated pathways downstream of mutant KRAS as a treatment approach for peritoneal mucinous malignancies.
by: Murali R Kuracha, et al.
Published: (2017-01-01)

Flavopiridol Synergizes with Sorafenib to Induce Cytotoxicity and Potentiate Antitumorigenic Activity in EGFR/HER-2 and Mutant RAS/RAF Breast Cancer Model Systems
by: Teddy S Nagaria, et al.
Published: (2013-08-01)

Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage
by: Zerbib, J, et al.
Published: (2024)

Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage
by: Johanna Zerbib, et al.
Published: (2024-09-01)

Cefotetan-bound human RKIP involves in Ras/Raf1/MEK/ERK signaling pathway
by: Guo Chenyun, et al.
Published: (2022-12-01)

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment
by: Clara Alcon, et al.
Published: (2022-04-01)

A pan-KRAS degrader for the treatment of KRAS-mutant cancers
by: Jie Yang, et al.
Published: (2024-06-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)

CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
by: Sara Costa-Cabral, et al.
Published: (2016-01-01)

Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition
by: Sarah E. Sheppard, et al.
Published: (2023-05-01)